-
FDA Approves new Initiation drug, ARISTADA INITIO, for Schizophrenia
- July 3, 2018
- Posted by: PharmaScroll
- Category:
No Comments -
NICE rejects Ocrevus for PPMS, citing cost concerns
- July 3, 2018
- Posted by: PharmaScroll
- Category:
-
Hypertension drug shows positive Ph 3 Parkinson’s results in mice
- July 3, 2018
- Posted by: PharmaScroll
- Category:
-
Biohaven to test Rimegepant as a preventive Migraine treatment as well
- July 1, 2018
- Posted by: PharmaScroll
- Category:
-
Galcanezumab reduces migraine days in patients failing on Botox
- July 1, 2018
- Posted by: PharmaScroll
- Category:
-
Phase 1 study of TRV250, for acute migraine, successfully completed by Trevena
- July 1, 2018
- Posted by: PharmaScroll
- Category:
-
New dose formulation for Nuplazid, in Parkinsons, approved by FDA
- July 1, 2018
- Posted by: PharmaScroll
- Category:
-
α-Linolenic acid can reduce disease activity in multiple sclerosis patients, study finds
- June 29, 2018
- Posted by: PharmaScroll
- Category:
-
Novartis presents new Aimovig data to reinforce its efficacy, safety and tolerability
- June 29, 2018
- Posted by: PharmaScroll
- Category:
-
New Migraine study, by Novartis, indicates decreased workplace efficiency of patients
- June 29, 2018
- Posted by: PharmaScroll
- Category: